Embraer (NYSE: ERJ), East West Bancorp Inc. (NASDAQ: EWBC), Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), Alaska Air (NYSE: ALK), Amyris Inc. (NASDAQ: AMRS), Columbia Sportswear (NASDAQ: COLM) and Embraer (NYSE: ERJ) were upgraded by analysts.
East West Bancorp Inc. (EWBC) was upgraded by FBR Capital from a “Market Perform” rating to an “Outperform” rating. They have a price target of $23.00 on the company.
Jazz Pharmaceuticals, Inc. (JAZZ) was upgraded by Jefferies (NYSE:JEF) from a “Hold” rating to a “Buy” rating. They have a price target of $52.00 on the company, up from $29.00.
Alaska Air (ALK) was upgraded by Dahlman Rose from a “Hold” rating to a “Buy” rating. They have a price target of $75.00 on the company.
Amyris Inc. (AMRS) was upgraded by Morgan Stanley (NYSE:MS) from an “Equal Weight” rating to an “Overweight” rating. They have a price target of $32.00 on the company.
Columbia Sportswear (COLM) was upgraded by McAdams Wright Ragen from a “Hold” rating to a “Buy” rating. They have a price target of $69.00 on the company.
Embraer (ERJ) was upgraded by JPMorgan Chase & Co. (NYSE:JPM) from a “Neutral” rating to an “Overweight” rating.
Showing posts with label Jazz Pharma. Show all posts
Showing posts with label Jazz Pharma. Show all posts
Tuesday, August 2, 2011
Tuesday, February 1, 2011
Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN), Human Genome (NASDAQ:HGSI) Could be Takeover Targets
With time and costs a major factor in the drug industry, companies appear to be hunting for takeover targets like Alexion (NASDAQ:ALXN), Cadence (NASDAQ:CADX), Cubist (NASDAQ:CBST), Dendreon (NASDAQ:DNDN) and Human Genome (NASDAQ:HGSI), which have a pipeline, or are close to developing a pipeline, with soon-to-be-approved drugs.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Others noted in a recent Barron's article as possible takeover candidates were Acorda (NASDAQ:ACOR), AMAG Pharmaceuticals (NASDAQ:AMAG), BioMarin (NASDAQ:BMRN), Cephalon (NASDAQ:CEPH), Jazz Pharma (NASDAQ:JAZZ), Onyx (NASDAQ:ONXX), United Therapeutics (NASDAQ:UTHR), and Salix Pharmaceuticals (NASDAQ:SLXP).
Some of the companies rose on the assertions, with Cadence closing Monday at $7.76, gaining $0.47, or 6.52 percent.
Subscribe to:
Posts (Atom)